Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

FY22 trading update: Fisher & Paykel Healthcare (ASX:FPH) share price in focus

The Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) share price is in focus after releasing a trading update for FY22.

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price is in focus after releasing a trading update for FY22.

FY22 update

This update is for the first four months of FY22, ending 31 July 2021.

Revenue for these four months was $583 million. In constant currency terms, that was a decline of 2% compared to the first four months of FY21 – that was when there was high demand due to COVID-19 in North America and Europe.

Of that revenue total, 74% was hospital product revenue and the other 26% from the homecare product group.

Hospital product revenue

The hospital product revenue was 3% lower in constant currency terms. This consisted of a 13% decline in hardware sales (which accounted for 34% of hospital sales) and a 2% rise in consumable sales (which accounted for 66% of hospital revenue).

Compared to pre-COVID levels, overall hardware volumes remained elevated. This was largely driven by some regions experiencing COVID-19 hospitalisation surges and requiring healthcare help.

Hardware sales in America and Europe and slumped 62%, whilst outside those regions hardware sales were up 42% and consumables grew 31%. It was demand higher that sent the Fisher & Paykel Healthcare share price higher.

The hospital consumable growth continues to reflect the clinical practice shift from invasive ventilation towards the use of Optiflow nasal high flow therapy. There was new applications consumables growth of 17% in constant currency.

Homecare product revenue

Fisher & Paykel saw 4% growth for this segment in the first four months, with 4% growth of obstructive sleep apnea masks.

Outlook for FY22 and the Fisher & Paykel Healthcare share price

Due to the uncertainty of vaccination rates, the effectiveness of vaccines against variants and public responses to COVID-19, the company said it wasn’t able to provide guidance for FY22.

The company isn’t expecting its hospital hardware revenue to continue at this elevated level for the rest of the year. However, it did note there is an increase in demand with hospitalisations in the US. Client choices about stock levels will have a sizeable impact on COVID-related product demand.

But, the longer-term impact is an increased installed base of hardware and increased global physician awareness and experience with therapies and products in hospitals. This is expected to result in an increased number of patients receiving the therapies and products for years to come.

Freight costs remain elevated and Fisher & Paykel Healthcare continues to grow its investment in R&D and advertising. That may suggest the EBITDA margin (EBITDA explained) may be a little lower.

The company is a quality business, but it’s hard to know what demand will look like in FY23 and onwards. There are other ASX growth shares that could be better ideas for growth for the (pre-open) value.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content